PT Suparma Tbk EBIT

The latest EBIT for SPMA.JK is $210B as of June 2026. That compares with $210B in the prior-year period — down 0.1% year over year. That is below the sector sector average of $2.5T. Investors often review this figure alongside PT Suparma Tbk's historical trend and sector peers before judging valuation or financial health.

Over the past year, SPMA.JK's EBIT moved from $210B to $210B — a 0.1% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in PT Suparma Tbk's operating scale or balance-sheet position.

Against its sector companies, SPMA.JK currently prints $210B for EBIT, while the sector average sits near $2.5T. That is roughly 91.6% below the sector mean. Large gaps often invite a closer look at PT Suparma Tbk's growth, margins, and balance sheet.

A EBIT figure of $210B for SPMA.JK is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $2.5T. Explore the charts below for those layers of context.

After noting SPMA.JK's EBIT ($210B), review year-over-year change from $210B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.